• THE BEGINNING...

    LIMPH was founded at Rutgers University - New Brunswick in Fall 2018. Our mission is to build next-generation biosensing technologies for a deeper understanding of immunology, individualized monitoring of infectious diseases, engineering the immune response, and developing point-of-care sensors for global health applications.

  • Smartphone Diagnostics

    Our research group is developing smartphone enabled point-of-care diagnostic sensors and systems. We are quantifying multiple biomarkers associated with diagnostics for many infectious diseases like HIV and Sepsis.

  • Multi-modal detection systems

    We are working on multiple technologies to perform multiplexing and biomarker detection. This includes monitoring personalized immune response of infected patients including quantifying cells, proteins, exosomes, micrpRNAs, and phagocytes in clinical studies.

Smartphone enabled Biosensors for Global Health

Smartphone enabled Point-of-Care Biosensors are being developed to quantify multiple biomolecules in biological samples for disease diagnostic applications. We can enumerate the bioentities from sub-micron to micron ranges in microfluidic devices in clinical studies.

Monitoring and Engineering Phagocytic Ability

We are developing a sensor to quantify the phagocytic ability of blood cells in infectious diseases. Further, we are coming up with biochemical and non-biochemical strategies to engineer phagocytic ability of blood cells in various immunological conditions.

Multiplexed Biomarker Detection Technologies

We are developing multiple technologies with collaborators to quantify multiple biomarkers in a single assay. We use barcoded particles including nano-electronic layered beads and patterned hydrogels synthesized using stop flow lithography.

Eco-friendly Nanoparticles composites for Biomedical Applications

We are synthesizing different modalities of eco-friendly silver nanoparticles including beads, rods, nanowires and using them for multiple applications including water purification, air filtration, antimicrobial applications and wound healing.

LIMPH's Mission Statement

The core objective of our research group is to achieve global health equity. To achieve this, we build next-generation biosensing technologies for a deeper understanding of immunology, individualized monitoring of infectious diseases, engineering the immune response, and developing point-of-care sensors for global health applications. Our strategy encompasses the comprehensive clinical translation pathway from biosensor development, characterization, and finally its validation in multi-center clinical studies.

About Research Group - Focus Areas

Core focus areas of our research group are:

  • Global Health: Our mission is to improve health and achieve equity in health in global settings by developing point-of-care technologies. We work on many diseases including HIV/AIDS, Cancer, Sepsis etc.
  • Next Generation Biosensor Development: We develop next generation biosensors for multiplexed inflammatory biomarker detection in various disease conditions for diagnostics and prognostics.
  • Personalized Patient Stratification: We develop predictive machine learning systems for personalized patient stratification by employing sensors and clinical data.
  • Immuno-Engineering: We develop novel methodologies to engineer and modulate the desired immune response using reconfigured therapeutics and novel non-biochemical techniques.